Theriva Biologics Inc. announced that it was unable to convene its Special Meeting of Stockholders on December 15, 2025, due to a lack of quorum. The meeting was called to seek shareholder approval for the issuance of up to 16,184,560 shares of common stock upon the exercise of certain purchase warrants issued under a warrant inducement agreement with institutional investors. The company is required to call additional stockholder meetings every 60 days until approval is obtained or the warrants are no longer outstanding. The date and time of a new special meeting will be announced, and new proxy materials will be filed and mailed as required.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Theriva Biologics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-121246), on December 15, 2025, and is solely responsible for the information contained therein.